Our results suggest that the novel combination of lapatinib and amiloride would be suitable for such ‘AR bypass NAT’ for the following reasons: (i) it would reduce tumor size by inducing apoptosis and (ii) should patients develop resistance to it, conventional AR-targeting treatments might still be effective (because lapatinib and amiloride would likely not be used in a post-recurrence setting) (iii) our data shows no effect of the combination on AR. This evidence concerns the gene AR and neoplasm.